MIRA Pharmaceuticals | 8-K: Current report
MIRA Pharmaceuticals | 8-K: Current report
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Clouston
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Yanez Michelle
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Shekhat Denil Nanji
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Del Giudice Matthew Paul
MIRA Pharmaceuticals | 8-K: Current report
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez
MIRA Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Whalen Matthew Pratt
MIRA Pharmaceuticals | 8-K: Current report
MIRA Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
MIRA Pharmaceuticals | 8-K: Current report
MIRA Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
MIRA Pharmaceuticals | 8-K: Current report
MIRA Pharmaceuticals | 8-K: Current report
MIRA Pharmaceuticals | 424B5: Prospectus
MIRA Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
MIRA Pharmaceuticals | 8-K: Current report
No Data